Status:

COMPLETED

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes

Diabetes Mellitus, Type 1

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the long-term safety of insulin aspart in the management of type 1 diabetes. An extension to the ANA/DCD/06...

Eligibility Criteria

Inclusion

  • Signed informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject)
  • The subject must have completed the ANA/DCD/065 trial

Exclusion

  • Impaired hepatic function
  • Impaired renal function
  • Total daily insulin requirements of more than 1.4 U/kg
  • Cardiac problems
  • Uncontrolled hypertension
  • Known or suspected allergy to trial product or related products
  • Current hypoglycaemic unawareness as judged by the investigator
  • Known or suspect abuse of alcohol or narcotics
  • Women breastfeeding or having the intention of becoming pregnant, or if judged not to be using adequate contraceptive measures (adequate measures are intrauterine device (IUD), oral contraception and barrier methods)
  • Any condition that the Investigator and/or Sponsor feels would interfere with trial participation or evaluation of results

Key Trial Info

Start Date :

December 22 1999

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 25 2002

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT00832182

Start Date

December 22 1999

End Date

November 25 2002

Last Update

February 23 2017

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Novo Nordisk Investigational Site

Zagreb, Croatia, 10 000

2

Novo Nordisk Investigational Site

Prague, Czechia, 10034

3

Novo Nordisk Investigational Site

Prague, Czechia, 12821

4

Novo Nordisk Investigational Site

Tel Litwinsky, Israel, 52621